Other

TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ
Dr. John Cush @RheumNow( View Tweet )
Assessment of Peripheral Arthritis in Spondyloarthritis Dr. Antoni Chan talks with Dr. Dafne Capelusnik about abstract POS0257 presented at the 2025 EULAR meeting in Barcelona. https://t.co/E6l6qvNnox https://t.co/gLbMjF406q

Links:

Dr. John Cush @RheumNow( View Tweet )
Trends and Innovations from Barcelona (6.20.2025) Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week. https://t.co/iEiQI8GACt https://t.co/X27CuZb5wH

Links:

Dr. John Cush @RheumNow( View Tweet )
Simple Measures are Effective in Knee Osteoarthritis Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of https://t.co/4VQpKQJwXu
Dr. John Cush @RheumNow( View Tweet )
IL-17 inhibitors - Long-term Extensions and Uveitis Dr. Peter Nash offers his perspective on data presented at the 2025 EULAR meeting in Barcelona. https://t.co/eQd0TcQn76 https://t.co/6Zog4LC8Aj

Links:

Dr. John Cush @RheumNow( View Tweet )
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/ppuzIB4iRf
Dr. John Cush @RheumNow( View Tweet )
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/B5tMq147L4
Dr. John Cush @RheumNow( View Tweet )
Eular 2025 PsA Topic Panel https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76

Links:

Dr. John Cush @RheumNow( View Tweet )
EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes. https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6

Links:

Dr. John Cush @RheumNow( View Tweet )
A new mechanism of action in SARD-ILD Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x
Dr. John Cush @RheumNow( View Tweet )
Not All About B Cells: Myeloid Related Inflammation in Lupus Pathogenesis Dr. Andrea Fava shares his perspectives from the EULAR 2025 meeting in Barcelona, Spain. https://t.co/8Lh02c3sy4 https://t.co/XX7wKovD9u

Links:

Dr. John Cush @RheumNow( View Tweet )
Secukinumab & Uveitis = Unclear? Post hoc study of 11 SEC RCTs finds lower uveitis risk in AxSpA (N 1980; SEC 150 1.29/100PYs vs 1.72/100PY in PBO), but not in PsA (N 2453; SEC 300 0.71/100PY vs  zero w/ placebo) https://t.co/Gv9HheBU7l https://t.co/SlnrLRwmmn

Links:

Dr. John Cush @RheumNow( View Tweet )
Nurse-Led Treat-to-Target Clinics New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems. https://t.co/sV8IHhnwbm https://t.co/IrJKvceyez

Links:

Dr. John Cush @RheumNow( View Tweet )

Join Drs. John J. Cush and Dr. Arthur Kavanaugh for the EULAR Rheumatology RoundUp — a dynamic, fast-paced discussion capturing the most impactful highlights, late-breaking data, and clinical takeaways from EULAR 2025. Tune in live on X-Live, Facebook Live, or YouTube Live for https://t.co/fcrWbwOLTx

Dr. John Cush @RheumNow( View Tweet )
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/2wloutoX8a

Links:

Dr. John Cush @RheumNow( View Tweet )
Expanding the IL-17 Therapeutic Landscape IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush @RheumNow( View Tweet )
The Value of Kidney Biopsy in Autoimmune Diseases Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain. https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl

Links:

Dr. John Cush @RheumNow( View Tweet )
ALTO: Long-term Outcomes of APIPPRA Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm

Links:

Dr. John Cush @RheumNow( View Tweet )
EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush @RheumNow( View Tweet )
pregnancy,doctor,consult

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns

Bella Mehta, MBBS, MS

While clinical comorbidities such as lupus nephritis, hypertension, and thrombocytopenia have traditionally dominated risk assessments, new findings presented at EULAR 2025 spotlight the critical—and often underrecognized—role of social determinants of health (SDOH) in shaping maternal outcomes

Read Article
Lessons on Uveitis and AxSpA Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm

Links:

Dr. John Cush @RheumNow( View Tweet )
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush @RheumNow( View Tweet )
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush @RheumNow( View Tweet )
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/GpC7QliKXH

Links:

Dr. John Cush @RheumNow( View Tweet )
Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

The War Rheum

Kathryn H. Dao, M.D.
blue and yellow arms and hands
The effects on rheumatologists and their patients living in Ukraine largely have been unseen by the world. At ACR Convergence 2024, I met Dr. Marta Dzhus who practices at St. Michael's Clinical Hospital in Kyiv; she shared her story with me about the humanitarian crisis in rheumatologic care in Ukraine because of the ongoing war. Here is an excerpt of our conversation. Read Post

Overlap Syndrome with ILD

Jack Cush, MD
Cush RheumThought ILD

How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?

Read Post
×